Aceclofenac is an oral non-steroidal anti-inflammatory drug (NSAID) with potent anti-inflammatory and analgesic properties. It belongs to the phenylacetic acid derivatives class and is structurally and pharmacologically related to diclofenac. Since its first approval in the European Union in 1990 and launch in Spain in 1992, aceclofenac has gained significant clinical acceptance worldwide, with approvals in 69 countries and an estimated exposure of about 171 million patients.
The drug is particularly valued for its efficacy in managing various inflammatory and painful conditions with a relatively favorable safety profile compared to other NSAIDs. This comprehensive review examines aceclofenac’s chemical properties, pharmaceutical forms, mechanism of action, pharmacokinetics, therapeutic applications, safety considerations, and regulatory status.
Chemical Structure and Properties
Aceclofenac (C₁₆H₁₃Cl₂NO₄) is chemically known as 2-[(2,6-dichlorophenyl)amino]phenylacetoxyacetic acid with a molecular weight of 354.18 g/mol. It is structurally an analog of diclofenac with slight modifications that enhance its pharmacokinetic profile and potentially improve its gastrointestinal tolerability.
According to the Biopharmaceutical Classification System (BCS), aceclofenac is classified as a Class II drug – poorly soluble but highly permeable. It is practically insoluble in water, which presents challenges for its formulation but benefits its ability to penetrate biological membranes.
The compound features a dichloroaniline ring connected to a phenylacetic acid moiety with an acetoxyacetic acid side chain. This unique chemical structure contributes to its specific binding characteristics with cyclooxygenase enzymes and its pharmacological properties.
Aceclofenac-Based Medicines List
Aceclofenac is marketed under various brand names globally. Here are eight prominent aceclofenac-based pharmaceutical products:
- Airtal/Biofenac (Gedeon Richter Plc.) – One of the most widely recognized brands globally
- Preservex (Almirall S.A.) – The reference product in the UK market
- Hifenac/Hifenac-P (Intas Pharmaceuticals) – Popular in the Indian market
- Aceclo/Aceclo SR (Aristo Pharmaceuticals) – Available in immediate and sustained-release formulations
- Movexx FC (Cipla Ltd.) – Film-coated tablet formulation
- Zerodol – Widely prescribed in several countries
- Aceflam (Julphar, UAE) – Common in Middle Eastern markets
- Flamace (Biomax Laboratories) – Available in multiple dosage forms
These medications are available in various formulations, including immediate-release tablets, sustained-release tablets, film-coated tablets, and in some regions, parenteral preparations.
Mechanism of Action
Aceclofenac exerts its therapeutic effects primarily through inhibition of cyclooxygenase (COX) enzymes, key mediators in the inflammatory cascade and prostaglandin synthesis pathway. The drug has demonstrated a preferential inhibition of COX-2 (IC50 of 0.77µM) over COX-1 (IC50 of >100µM), which contributes to its improved gastrointestinal tolerability compared to traditional NSAIDs.
The pharmacological activity of aceclofenac involves several complementary mechanisms:
- Inhibition of prostaglandin synthesis, particularly PGE2, which mediates pain, inflammation, and fever.
- Suppression of inflammatory cytokines, including interleukins (IL-1β, IL-6) and tumor necrosis factor (TNF), which play crucial roles in the inflammatory process.
- Interference with neutrophil adhesion to the endothelium by decreasing the expression of L-selectin (CD62L), thereby reducing inflammatory cell migration to sites of inflammation.
- Stimulation of glycosaminoglycan synthesis in human osteoarthritic cartilage, potentially mediated through its inhibitory action on IL-1 production and activity, contributing to its chondroprotective effects.
Additionally, aceclofenac undergoes biotransformation to several metabolites, including 4′-hydroxyaceclofenac, which also contribute to its anti-inflammatory and analgesic effects.
Pharmacokinetics
Aceclofenac demonstrates favorable pharmacokinetic properties that contribute to its clinical efficacy:
Following oral administration, aceclofenac is rapidly and completely absorbed from the gastrointestinal tract, reaching peak plasma concentrations approximately 1.25 to 3.0 hours after ingestion. The drug exhibits excellent tissue penetration, particularly into synovial fluid, where concentrations reach approximately 57% of plasma levels – a characteristic especially relevant for its efficacy in joint disorders.
The volume of distribution is approximately 25 liters, indicating moderate tissue distribution. Aceclofenac exhibits extensive protein binding (>99%), primarily to albumin, which influences its distribution and elimination characteristics.
The drug primarily circulates in its unchanged form, with the major metabolite detected in plasma being 4′-hydroxyaceclofenac. Metabolism occurs primarily in the liver through cytochrome P450 enzymes, and no significant accumulation occurs with regular dosing.
The plasma half-life of aceclofenac is approximately 4 hours, supporting its typical twice-daily dosing regimen. Elimination occurs primarily via renal excretion, with approximately two-thirds of the administered dose excreted in urine, mainly in the form of hydroxymetabolites.
Therapeutic Uses
Aceclofenac is approved for various inflammatory and painful conditions across different countries. The table below summarizes its primary therapeutic indications:
| Condition | Description | Typical Dosage |
|---|---|---|
| Osteoarthritis | Management of pain and inflammation in degenerative joint disease | 100 mg twice daily |
| Rheumatoid Arthritis | Treatment of inflammatory joint conditions with autoimmune etiology | 100 mg twice daily |
| Ankylosing Spondylitis | Relief of symptoms in inflammatory spinal arthritis | 100 mg twice daily |
| Low Back Pain | Management of acute and chronic lumbar pain | 100 mg twice daily |
| Dental Pain | Relief of post-operative and inflammatory dental pain | 100 mg twice daily |
| Scapulohumeral Periarthritis | Treatment of shoulder inflammation and associated pain | 100 mg twice daily |
| Tendinitis & Sprains | Management of soft tissue inflammation | 100 mg twice daily |
| Primary Dysmenorrhea | Relief of menstrual pain | 100 mg twice daily |
Side Effects
Like other NSAIDs, aceclofenac is associated with various adverse effects, though it generally demonstrates better gastrointestinal tolerability than many traditional NSAIDs. The incidence of gastric ulcerogenicity of aceclofenac has been reported to be significantly lower – 2-fold less than naproxen, 4-fold less than diclofenac, and 7-fold less than indomethacin.
Common side effects (affecting up to 1 in 10 people) include:
- Dizziness
- Nausea
- Diarrhea
- Elevated liver enzymes in the blood
Uncommon side effects (affecting up to 1 in 100 people) include:
- Flatulence (gas)
- Gastritis (inflammation of stomach lining)
- Constipation
- Vomiting
- Mouth ulcers
- Skin rashes and itching
- Increased blood urea and creatinine levels
Rare side effects (affecting up to 1 in 1,000 people) include:
- Hypersensitivity reactions
- Visual disturbances
- Heart failure
- Hypertension
- Gastrointestinal bleeding or ulceration
Very rare but serious side effects (affecting up to 1 in 10,000 people) include:
- Severe cutaneous reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis)
- Hepatotoxicity
- Renal dysfunction
- Severe hypersensitivity reactions
- Hematological disorders
Drug Interactions
Aceclofenac, like other NSAIDs, has the potential for numerous drug interactions that may affect its efficacy or safety profile. As an analog of diclofenac, many of its interactions are similar to those observed with diclofenac, which has documented interactions with over 440 drugs.
Major interactions that require careful monitoring include:
- Anticoagulants and antiplatelets (warfarin, clopidogrel): Increased risk of bleeding when co-administered with aceclofenac
- Other NSAIDs and aspirin: Concomitant use may increase the risk of gastrointestinal adverse effects
- Corticosteroids: Enhanced risk of gastrointestinal ulceration and bleeding
- ACE inhibitors and ARBs: Possible reduction in antihypertensive efficacy and increased risk of renal impairment, particularly in the elderly or dehydrated patients
- Diuretics: Reduced diuretic effectiveness and potential increased nephrotoxicity
- Lithium and methotrexate: Aceclofenac may increase plasma concentrations of these drugs, potentially leading to toxicity
- Cyclosporine: Increased risk of nephrotoxicity when NSAIDs are co-administered with cyclosporine
Monitoring for these interactions and appropriate dose adjustments may be necessary when aceclofenac is prescribed alongside these medications.
Safety Considerations
Several important safety considerations should be taken into account when prescribing aceclofenac:
Aceclofenac is contraindicated in patients with:
- Known hypersensitivity to aceclofenac or other NSAIDs
- History of asthma, urticaria, or allergic reactions precipitated by aspirin or other NSAIDs
- Active or history of recurrent peptic ulceration or gastrointestinal bleeding
- Severe heart failure, hepatic failure, or renal failure
- Third trimester of pregnancy
Special caution is needed in patients with:
- Cardiovascular risk factors (hypertension, hyperlipidemia, diabetes, smoking) due to potential increased risk of thrombotic events
- History of gastrointestinal disease
- Impaired renal or hepatic function
- Elderly patients, who are more susceptible to adverse effects
- Asthma or allergic conditions
- Systemic lupus erythematosus or mixed connective tissue disorders
- First or second trimester of pregnancy
- Breastfeeding mothers (aceclofenac is not recommended)
Patients should be advised to take aceclofenac with food to minimize gastrointestinal irritation, avoid alcohol consumption during treatment, and report any signs of gastrointestinal bleeding, skin reactions, or unusual symptoms promptly.
Regulatory Status
Aceclofenac was patented in 1983 and first received regulatory approval for medical use in 1992. It was initially approved in the European Union in 1990 and launched in Spain in 1992. Since then, it has received marketing authorization in 69 countries worldwide.
In the United Kingdom, Preservex (aceclofenac) was first authorized on April 24, 1995, to Prodesfarma S.A., and in 2011, the UK granted Astron Research Limited a Marketing Authorization for Aceclofenac 100 mg film-coated Tablets.
The drug is available in various formulations, with the most common being 100 mg immediate-release tablets and 200 mg sustained-release tablets. In some countries, parenteral formulations (injections) and topical preparations are also available.
Aceclofenac is classified as a prescription-only medicine in most countries, reflecting the need for medical supervision during its use. Pricing varies significantly by country and formulation, with generic versions generally available at lower cost than branded products.
Conclusion
Aceclofenac represents an important therapeutic option in the NSAID class for the management of various painful and inflammatory conditions. Its relative COX-2 selectivity, favorable efficacy profile, and potentially improved gastrointestinal tolerability compared to some traditional NSAIDs make it a valuable alternative for patients who require long-term anti-inflammatory therapy.
Despite its benefits, aceclofenac shares the class-wide concerns associated with NSAIDs, including cardiovascular, renal, and gastrointestinal risks. Appropriate patient selection, medication counseling, and monitoring are essential to maximize therapeutic outcomes while minimizing adverse effects.
Ongoing research continues to explore the unique properties of aceclofenac, its specific mechanisms of action, and potential new applications in various painful and inflammatory conditions. As with all NSAIDs, the balance between efficacy and safety remains paramount in clinical decision-making regarding the use of aceclofenac.
